MedTrace Logo

A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A

NCT06916130 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-04-08

No results posted yet for this study

Summary

Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-120 in healthy subjects.

Conditions

  • Gastroesophageal Reflux Disease (GERD)

Interventions

DRUG

AD-120A

Administered before the breakfast during 7 days, Oral, Tablet

DRUG

AD-120

Administered before the breakfast during 7 days, Oral, Tablet

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-21
Primary Completion
2025-09-01
Completion
2025-09-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06916130 on ClinicalTrials.gov